Canonic Ltd., focused on the development of medical grade cannabis products and a wholly owned subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE:EVGN), is launching its second-generation products in Israel. The design of the new products leverages market feedback since Canonic's launch of its first-generation products in Israel in September 2021. The first new product from the second-generation product-line is expected to debut for patients in early October 2022. The rest of the second-generation product line will follow during the last quarter of the year through the first quarter of 2023.

Canonic's second-generation …

Full story available on Benzinga.com